The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive ...
Investigators evaluated patient-reported outcomes and tolerability of capivasertib plus abiterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.
Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...
Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real ...
The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results